Economic Evaluation of Fulvestrant 500 mg Versus Generic Nonsteroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer in the United Kingdom

Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach

Fred S. Guthery, Kenneth P. Burnham, David Anderson · Journal of Wildlife Management · 2003 · 42.2K citations · Full text

Computing, Biostatistics, Bayesian Data Analysis +16

Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine Treatment

Anthony Howell, J.F.R. Robertson, J. Albano et al. · Journal of Clinical Oncology · 2002 · 669 citations

Medicine, Oncology, Pharmacology +14

Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American Trial

C. Kent Osborne, John Pippen, Stephen E. Jones et al. · Journal of Clinical Oncology · 2002 · 643 citations

Medicine, Oncology, Pharmacology +14

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer

Angelo Di Leo, Guy Jérusalem, Luboš Petruželka et al. · Journal of Clinical Oncology · 2010 · 633 citations · Full text

Medicine, Oncology, Pharmacology +16

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.

Aman U. Buzdar, W. Jonat, Anthony Howell et al. · PubMed · 1998 · 418 citations

Medicine, Oncology, Pharmacology +15